MARKET

DFFN

DFFN

Diffusion Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.5749
+0.0150
+2.68%
Closed 19:07 07/29 EDT
OPEN
0.5700
PREV CLOSE
0.5599
HIGH
0.5999
LOW
0.5455
VOLUME
1.85M
TURNOVER
--
52 WEEK HIGH
1.850
52 WEEK LOW
0.5099
MARKET CAP
58.58M
P/E (TTM)
-2.0137
1D
5D
1M
3M
1Y
5Y
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers
Benzinga · 1d ago
Stocks That Hit 52-Week Lows On Friday
    On Friday morning, 68 companies hit new 52-week lows.
Benzinga · 07/16 14:16
The Daily Biotech Pulse: Moderna To Join S&P 500 Index, Thumbs Down For FibroGen's Anemia Drug, Corvus Shelves COVID Study
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 15)
Benzinga · 07/16 11:37
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers
Benzinga · 07/15 20:34
DFFN: TSC Causes Dose Dependent Increase in Tissue Oxygenation in TCOM Trial…
By David Bautz, PhD NASDAQ:DFFN READ THE FULL DFFN RESEARCH REPORT
Benzinga · 07/11 11:00
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers Delcath Systems (NASDAQ:DCTH) stock increased by 8.87% to $11.9 during Friday's after-market session. This security traded at a volume of 379 shares come close, making up 0.45% of its average volume over the last 100 days. The company's market cap...
Benzinga · 07/09 21:20
Diffusion Pharma's TSC Shows Encouraging Effects On Oxygenation
Diffusion Pharmaceuticals Inc (NASDAQ: DFFN) has announced topline results from the Phase 1 trial of its lead product candidate, trans sodium crocetinate (TSC). In the trial, transcutaneous oxygen monitoring (TCOM) was used to measure the direct pharmacody...
Benzinga · 06/30 15:14
Diffusion Pharmaceuticals posts positive trend in oxygenation from TCOM trial
Diffusion Pharmaceuticals (DFFN) announces positive topline results from the company’s Phase 1 trial of its lead product candidate, trans sodium crocetinate (“TSC”).Shares up more than 12% premarket.In the trial, transcutaneous oxygen monitoring (“TCOM”)
Seekingalpha · 06/30 11:59
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of DFFN. Analyze the recent business situations of Diffusion Pharms through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average DFFN stock price target is 2.000 with a high estimate of 2.000 and a low estimate of 2.000.
EPS
Institutional Holdings
Institutions: 41
Institutional Holdings: 10.79M
% Owned: 10.59%
Shares Outstanding: 101.90M
TypeInstitutionsShares
Increased
9
5.66M
New
9
616.42K
Decreased
2
1.03M
Sold Out
7
263.36K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
No Data
No Data
About DFFN
Diffusion Pharmaceuticals Inc. is a clinical-stage biotechnology company. The Company is focused on developing standard-of-care treatments, including radiation therapy and chemotherapy. The Company's lead product candidate, transcrocetinate sodium, also known as trans sodium crocetinate (TSC) is used in various cancer types, in which tumor oxygen deprivation (hypoxia) is known to diminish the effectiveness of treatments. The Company's Diffusion's technology is targeted at overcoming treatment-resistance in solid cancerous tumors by combining its lead product candidate, TSC, with standard-of-care radiation and chemotherapy regimens, thus effecting a better patient survival outcome without the addition of harmful side effects. Its clinical development plan targets TSC at the radiation and chemotherapy sensitization of hypoxic tumor types, with an initial focus on primary brain cancer (glioblastoma or GBM), pancreatic cancer, and brain metastases.

Webull offers kinds of Diffusion Pharmaceuticals Inc stock information, including NASDAQ:DFFN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DFFN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading DFFN stock methods without spending real money on the virtual paper trading platform.